[
  {
    "ts": null,
    "headline": "Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.",
    "summary": "The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.",
    "url": "https://finnhub.io/api/news?id=8b5d9a7a8877330f2718e060c2160c257457621695bd6104cab575f4ca586748",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760383440,
      "headline": "Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.",
      "id": 137070483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Trump administration has promised to delay sector-specific tariffs for both firms, and more drugmakers could join the club.",
      "url": "https://finnhub.io/api/news?id=8b5d9a7a8877330f2718e060c2160c257457621695bd6104cab575f4ca586748"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal",
    "summary": "PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.",
    "url": "https://finnhub.io/api/news?id=793dc42c7503b8113b114c530d25a2d115a9967777f9a9d4030594c014e66b00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760381400,
      "headline": "Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal",
      "id": 137070694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.",
      "url": "https://finnhub.io/api/news?id=793dc42c7503b8113b114c530d25a2d115a9967777f9a9d4030594c014e66b00"
    }
  },
  {
    "ts": null,
    "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
    "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760377200,
      "headline": "AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve",
      "id": 137070417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=1480f66d706d835623c6a351a69c2d21b03fe4681b3b19910e0dc7f1cd409960"
    }
  },
  {
    "ts": null,
    "headline": "This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year",
    "summary": "This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year",
    "url": "https://finnhub.io/api/news?id=f225c0f067c0594c34225a0852d39a5a3245f31e9161a1b424adf00d82902955",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760375070,
      "headline": "This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year",
      "id": 137079655,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year",
      "url": "https://finnhub.io/api/news?id=f225c0f067c0594c34225a0852d39a5a3245f31e9161a1b424adf00d82902955"
    }
  },
  {
    "ts": null,
    "headline": "Miners prosper as FTSE 100 makes steady progress",
    "summary": "On the FTSE 100, gold miners Fresnillo and Endeavour Mining leapt 9.1% and 11% respectively.",
    "url": "https://finnhub.io/api/news?id=db26f71f7a0a08480fab5df8fa3f21e721cfa497b203a00e93cbd194413fd94e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760372711,
      "headline": "Miners prosper as FTSE 100 makes steady progress",
      "id": 137068775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On the FTSE 100, gold miners Fresnillo and Endeavour Mining leapt 9.1% and 11% respectively.",
      "url": "https://finnhub.io/api/news?id=db26f71f7a0a08480fab5df8fa3f21e721cfa497b203a00e93cbd194413fd94e"
    }
  },
  {
    "ts": null,
    "headline": "New US biotech hubs showing potential amid onshoring request",
    "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
    "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760367424,
      "headline": "New US biotech hubs showing potential amid onshoring request",
      "id": 137068535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the market.",
      "url": "https://finnhub.io/api/news?id=de77e07e9f38aa41868ba917d2e511b15e0cd2fbbb726d8aed94105baf42138a"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=0e99976ce99098b5c9601f8606beddaa780affc8a4261999078917203800062e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760360403,
      "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
      "id": 137068777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=0e99976ce99098b5c9601f8606beddaa780affc8a4261999078917203800062e"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Pfizer Be in 5 Years?",
    "summary": "Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.",
    "url": "https://finnhub.io/api/news?id=8318b85b2cb7d4f5acb374b4a3e33a9f99d7ec5c935c49159d7fcb71cfc09c80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760359500,
      "headline": "Where Will Pfizer Be in 5 Years?",
      "id": 137068778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.",
      "url": "https://finnhub.io/api/news?id=8318b85b2cb7d4f5acb374b4a3e33a9f99d7ec5c935c49159d7fcb71cfc09c80"
    }
  },
  {
    "ts": null,
    "headline": "Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress",
    "summary": "– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc.",
    "url": "https://finnhub.io/api/news?id=32f8b76fb0fc7b5c530ba9b82b673603214e16c78db754df91c555a4c02f8852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760353200,
      "headline": "Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress",
      "id": 137066432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc.",
      "url": "https://finnhub.io/api/news?id=32f8b76fb0fc7b5c530ba9b82b673603214e16c78db754df91c555a4c02f8852"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025",
    "summary": "NEW YORK, October 13, 2025--Pfizer Inc. (NYSE: PFE, \"Pfizer\") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.",
    "url": "https://finnhub.io/api/news?id=d7909173b120843fa0f43b26f7448c195831d98b70c11e146be0775c4cc18677",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760352300,
      "headline": "Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025",
      "id": 137066433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, October 13, 2025--Pfizer Inc. (NYSE: PFE, \"Pfizer\") will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases.",
      "url": "https://finnhub.io/api/news?id=d7909173b120843fa0f43b26f7448c195831d98b70c11e146be0775c4cc18677"
    }
  },
  {
    "ts": null,
    "headline": "Why Biotech’s Rally Can Last This Time",
    "summary": "After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.  Whether the run continues will depend on several factors: continued funding, a predictable regulatory environment, positive trial results, and steady deal activity.  Asad Haider,  head of U.S. healthcare equity research at Goldman Sachs, notes that biotech had moved in lockstep with the Russell 2000 small-cap index for much of the year amid bets on the trajectory of interest rates.",
    "url": "https://finnhub.io/api/news?id=fe355e46fcea064ffc035772d22d9b0caba235c8daeffd0526075c68989e1f02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760347800,
      "headline": "Why Biotech’s Rally Can Last This Time",
      "id": 137066434,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus.  Whether the run continues will depend on several factors: continued funding, a predictable regulatory environment, positive trial results, and steady deal activity.  Asad Haider,  head of U.S. healthcare equity research at Goldman Sachs, notes that biotech had moved in lockstep with the Russell 2000 small-cap index for much of the year amid bets on the trajectory of interest rates.",
      "url": "https://finnhub.io/api/news?id=fe355e46fcea064ffc035772d22d9b0caba235c8daeffd0526075c68989e1f02"
    }
  }
]